Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate
NCT ID: NCT00139061
Last Updated: 2007-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
128 participants
INTERVENTIONAL
2005-03-31
2006-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To assess the HDL-C increase and non-HDL lowering effect of torcetrapib/atorvastatin vs. fenofibrate.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Torcetrapib/Atorvastatin
Fenofibrate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men and women at least 18 years of age
Exclusion Criteria
* Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
* Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
* Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Angers, , France
Pfizer Investigational Site
Angers, , France
Pfizer Investigational Site
Bordeaux Cauderan, , France
Pfizer Investigational Site
Briollay, , France
Pfizer Investigational Site
Dijon, , France
Pfizer Investigational Site
Hagondange, , France
Pfizer Investigational Site
Haut-Mauco, , France
Pfizer Investigational Site
Jarny, , France
Pfizer Investigational Site
Lille, , France
Pfizer Investigational Site
Mars-la-Tour, , France
Pfizer Investigational Site
Metz, , France
Pfizer Investigational Site
Monguilhem, , France
Pfizer Investigational Site
Mont-de-Marsan, , France
Pfizer Investigational Site
Mont-de-Marsan, , France
Pfizer Investigational Site
Mont-de-Marsan, , France
Pfizer Investigational Site
Mont-de-Marsan, , France
Pfizer Investigational Site
Moûtiers, , France
Pfizer Investigational Site
Mûrs-Erigné, , France
Pfizer Investigational Site
Nantes, , France
Pfizer Investigational Site
Pouilly-en-Auxois, , France
Pfizer Investigational Site
Saint-Justin, , France
Pfizer Investigational Site
Saint-Martin-d'Oney, , France
Pfizer Investigational Site
Seysses, , France
Pfizer Investigational Site
Strasbourg, , France
Pfizer Investigational Site
Thouars, , France
Pfizer Investigational Site
Tiercé, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5091034
Identifier Type: -
Identifier Source: org_study_id